Zlotta AR, Schulman CC. Can survival be prolonged for pa- tients with hormone-resistant prostate cancer. Lancet 2001;357:26.Zlotta A. R., Schulman C. C., "Can survival be prolonged for patients with hormone- resistant prostate cancer?", Lancet, 357(9253), pp.326-327, 2001....
Convergent evolution of p38/MAPK activation in hormone resistant prostate cancer mediates pro-survival, immune evasive, and metastatic phenotypes Kathryn E. Ware, Santosh Gupta, Jared Eng, Gabor Kemeny, Bhairavy J. Puviindran...
Cancer Res, 41 (1981), pp. 5070-5074 Google Scholar 6. Miranda E, Miller JT, Ahmann FR Analysis of survival characteristics and prognostic factors in 148 patients with hormone-resistant (stage D3) prostate cancer North American Conference on Cancer in Hispanics (1991), p. A33 Google Scholar...
If this happens, your cancer is considered castrate-resistant, and hormone deprivation therapy is no longer an effective treatment. You’ll also get other blood tests to see if the cancer is affecting other parts of your body like your liver, kidneys, or bones. Scans will show how well your...
In conclusion, there have been impressive efforts to identify new cellular targets for the treatment of hormone-refractory disease. It appears that in some cases, survival may be extended; however, further prospective trials are necessary to confirm these observations.DOI...
Inevitably and unpredictably, metastatic disease treated with hormone therapy becomes androgen-independent (or, conversely, hormone-resistant) prostate cancer, defined by either clinical or PSA progression in the face of a castrated level of testosterone. Until recently, such patients were relegated to ...
A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody, against the insulin-like growth factor-1 receptor, as monotherapy in patients with metastatic, asymptomatic castration-resistant prostate cancer. J Clin Oncol. 2009;27:269s. suppl; abstr 5142 ...
No systemic therapy has led to prolongation of life in patients with hormone resistant prostate cancer though secondary hormone treatment and chemotherapy have resulted in an about 30% response rate. The main goal of treatment is palliation and improvement of quality of life, the former aim ...
Secondary end points include overall survival, time from randomization to the date of death from any cause, time from randomization to the date of first castration-resistant event, time to initiation of subsequent anti-cancer therapy, time to prostate-specific antigen (PSA) ...
The proven survival benefit of docetaxel-based therapy provides a framework for the development of new combination regimens These new treatments are focused on improving survival while maintaining or improving toxicity. Crucial to the development of rational therapy for hormone-resistant pr...